CD33 and acute myeloid leukemia: The first targeted therapy that was based on the surface antigen expression for AML was an anti-CD33 monoclonal antibody-drug conjugate named gemtuzumab ozogamicin, which was developed in 2000, and was withdrawn from the market in 2010.